EU/3/18/2087

About

On 19 November 2018, orphan designation (EU/3/18/2087) was granted by the European Commission to Consejo Superior de Investigaciones Cientificas, Spain, for etamsylate for the treatment of hereditary haemorrhagic telangiectasia.

The sponsorship was transferred to Dobecure S.L., Spain in June 2020.

Key facts

Active substance
Etamsylate
Disease / condition
Treatment of hereditary haemorrhagic telangiectasia
Date of first decision
19/11/2018
Outcome
Positive
EU designation number
EU/3/18/2087

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Dobecure S.L.
Calle De San Emilio 6 Local 1
28017 Madrid
Spain
Tel: +34 691 494 049
E-mail: alfonso.garcia@dobecure.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating